Adiponectin: a link between obesity and cancer
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Adiponectin, an insulin-sensitising hormone produced by adipocytes, has direct antidiabetic, antiatherogenic, anti-inflammatory and antiangiogenic properties. Circulating adiponectin levels are lower in obesity, a disease state that is associated with certain malignancies. Recently, accumulating evidence suggests that adiponectin may have an important protective role in carcinogenesis. There is also evidence that at least some, if not most, cancer cell types express adiponectin receptors; thus adiponectin may act on tumour cells directly by binding and activating adiponectin receptors and downstream signalling pathways. Through its antiangiogenic properties, and also possibly through other mechanisms regulating cell proliferation discussed in this review, adiponectin may prove to be an effective novel anticancer agent. Large association and prospective studies to assess adiponectin levels in relation to risk from cancer, as well as mechanistic studies to prove adiponectin's role in the development of malignancies, and interventional trials to address potential roles of adiponectin in cancer pathogenesis and therapeutics are needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults
Calle, E. E., Rodriguez, C., Walker-Thurmond, K., & Thun, M. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021423 · Cited by 7,696
Adipose Tissue as an Endocrine Organ
Kershaw, E. E., & Flier, J. S. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0395 · Cited by 5,522
Yamauchi, T., Kamon, J., Waki, H., Terauchi, Y., Kubota, N., Hara, K., Mori, Y., Ide, T., Murakami, K., Tsuboyama-Kasaoka, N., et al. (2001) · Nature Medicine · doi:10.1038/90984 · Cited by 4,915
Paradoxical Decrease of an Adipose-Specific Protein, Adiponectin, in Obesity
Arita, Y., Kihara, S., Ouchi, N., Takahashi, M., Maeda, K., Miyagawa, J.-I., Hotta, K., Shimomura, I., Nakamura, T., Miyaoka, K., et al. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0255 · Cited by 4,856
Kopelman, P. G. (2000) · Nature · doi:10.1038/35007508 · Cited by 4,795 · cited 1×
“The number of obese individuals is expected to continue to rise such that by the year 2030 it is anticipated that close to 50% of the US or close to 30% of the European population will be obese [2].”
BackgroundYamauchi, T., Kamon, J., Minokoshi, Y., Ito, Y., Waki, H., Uchida, S., Yamashita, S., Noda, M., Kita, S., Ueki, K., et al. (2002) · Nature Medicine · doi:10.1038/nm788 · Cited by 4,238 · cited 2×
“, AMPK activation by adiponectin leads to increase fatty-acid oxidation, glucose uptake and lactate production in muscle, and reduction of molecules involved in gluconeogenesis in the liver, and thus reduction of glucose levels in vivo) [58,60].”
BackgroundSignal transduction by the JNK group of MAP kinases
Davis, R. J. (2000) · Cell · doi:10.1016/s0092-8674(00)00116-1 · Cited by 4,237 · cited 2×
“It is also a crucial mediator of obesity and insulin resistance [138,139].”
BackgroundTSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival
Inoki, K., Zhu, T., & Guan, K.-L. (2003) · Cell · doi:10.1016/s0092-8674(03)00929-2 · Cited by 3,914
Weyer, C., Funahashi, T., Tanaka, S., Hotta, K., Matsuzawa, Y., Pratley, R. E., & Tataranni, P. A. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.5.7463 · Cited by 3,541
A central role for JNK in obesity and insulin resistance
Hirosumi, J., Tuncman, G., Chang, L., Görgün, C. Z., Uysal, K. T., Maeda, K., Karin, M., & Hotamisligil, G. S. (2002) · Nature · doi:10.1038/nature01137 · Cited by 3,359 · cited 1×
“It is also a crucial mediator of obesity and insulin resistance [138,139].”
BackgroundCloning of adiponectin receptors that mediate antidiabetic metabolic effects
Yamauchi, T., Kamon, J., Ito, Y., Tsuchida, A., Yokomizo, T., Kita, S., Sugiyama, T., Miyagishi, M., Hara, K., Tsunoda, M., et al. (2003) · Nature · doi:10.1038/nature01705 · Cited by 3,176
Adiponectin and Adiponectin Receptors
Kadowaki, T., & Yamauchi, T. (2005) · Endocrine Reviews · doi:10.1210/er.2005-0005 · Cited by 2,634
The adipocyte-secreted protein Acrp30 enhances hepatic insulin action
Berg, A. H., Combs, T. P., Du, X., Brownlee, M., & Scherer, P. E. (2001) · Nature Medicine · doi:10.1038/90992 · Cited by 2,526
Adipose Tissue as an Endocrine Organ
Ahima, R. S., & Flier, J. S. (2000) · Trends in Endocrinology & Metabolism · doi:10.1016/s1043-2760(00)00301-5 · Cited by 1,608
Cnop, M., Havel, P. J., Utzschneider, K. M., Carr, D. B., Sinha, M. K., Boyko, E. J., Retzlaff, B. M., Knopp, R. H., Brunzell, J. D., & Kahn, S. E. (2003) · Diabetologia · doi:10.1007/s00125-003-1074-z · Cited by 1,483
Yang, W.-S., Lee, W.-J., Funahashi, T., Tanaka, S., Matsuzawa, Y., Chao, C.-L., Chen, C.-L., Tai, T.-Y., & Chuang, L.-M. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.8.3815 · Cited by 1,181
Pajvani, U. B., Hawkins, M., Combs, T. P., Rajala, M. W., Doebber, T., Berger, J. P., Wagner, J. A., Wu, M., Knopps, A., Xiang, A. H., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311113200 · Cited by 1,163
Tomas, E., Tsao, T.-S., Saha, A. K., Murrey, H. E., Zhang, C. C., Itani, S. I., Lodish, H. F., & Ruderman, N. B. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.222657499 · Cited by 973
Insulin, Insulin-Like Growth Factors and Colon Cancer: A Review of the Evidence
Giovannucci, E. (2001) · The Journal of Nutrition · doi:10.1093/jn/131.11.3109s · Cited by 959
Androgens Decrease Plasma Adiponectin, an Insulin-Sensitizing Adipocyte-Derived Protein
Nishizawa, H., Shimomura, I., Kishida, K., Maeda, N., Kuriyama, H., Nagaretani, H., Matsuda, M., Kondo, H., Furuyama, N., Kihara, S., et al. (2002) · Diabetes · doi:10.2337/diabetes.51.9.2734 · Cited by 837 · cited 1×
“3 Predictors of serum levels Women have higher adiponectin levels than men independently of fat mass or distribution, probably due to differences in circulating estrogens or androgens [72,73].”
BackgroundOuchi, N., Kobayashi, H., Kihara, S., Kumada, M., Sato, K., Inoue, T., Funahashi, T., & Walsh, K. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310389200 · Cited by 759 · cited 1×
“fAd stimulates the differentiation of human umbilical vein endothelial cells into a capillary-like structure by promoting cross talk between AMP-activated protein kinase and Akt signalling [126].”
BackgroundLevy, D. E., & Lee, C.-K. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215650 · Cited by 734
A prospective study of obesity and cancer risk (Sweden)
Wolk, A., Gridley, G., Svensson, M., Nyrén, O., McLaughlin, J. K., Fraumeni, J. F., & Adami, H.-O. (2001) · Cancer Causes & Control · doi:10.1023/a:1008995217664 · Cited by 581 · cited 2×
“Obesity not only increases the risk of insulin resistance/Type 2 diabetes dramatically but has also been identified as a risk factor for several cancers, such as breast, endometrial, colon and rectal, kidney, pancreatic, biliary, ovarian, cervical, liver and prostate cancers [3].”
BackgroundTsuchida, A., Yamauchi, T., Ito, Y., Hada, Y., Maki, T., Takekawa, S., Kamon, J., Kobayashi, M., Suzuki, R., Hara, K., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402367200 · Cited by 550
Combs, T. P., Berg, A. H., Rajala, M. W., Klebanov, S., Iyengar, P., Jimenez-Chillaron, J. C., Patti, M. E., Klein, S. L., Weinstein, R. S., & Scherer, P. E. (2003) · Diabetes · doi:10.2337/diabetes.52.2.268 · Cited by 544
AMPK, the metabolic syndrome and cancer
Luo, Z., Saha, A. K., Xiang, X., & Ruderman, N. B. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.12.011 · Cited by 426 · cited 4×
“Thus AMPK phosphorylates and activates tuberous sclerosis complex 2 that leads to the inhibition of mTOR and its downstream effector kinase S6K, thus negatively regulating protein synthesis [130].”
BackgroundInfluentialAdiponectin and Future Coronary Heart Disease Events Among Men With Type 2 Diabetes
Schulze, M. B., Shai, I., Rimm, E. B., Li, T., Rifai, N., & Hu, F. B. (2005) · Diabetes · doi:10.2337/diabetes.54.2.534 · Cited by 365 · cited 1×
“Higher adiponectin levels are associated with a moderate decrease in risk for coronary heart disease in diabetic men [93] and with better glycaemic control, more favourable lipid profile and reduced inflammation in diabetic women [94].”
BackgroundAdiponectin is synthesized and secreted by human and murine cardiomyocytes
Piñeiro, R., Iglesias, M. J., Gallego, R., Raghay, K., Eiras, S., Rubio, J., Diéguez, C., Gualillo, O., González-Juanatey, J. R., & Lago, F. (2005) · FEBS Letters · doi:10.1016/j.febslet.2005.07.098 · Cited by 350 · cited 1×
“Although there is recent evidence for adiponectin production by cardiomyocytes [41] and placenta [42], the clinical significance of these findings remains to be elucidated.”
BackgroundWaki, H., Yamauchi, T., Kamon, J., Kita, S., Ito, Y., Hada, Y., Uchida, S., Tsuchida, A., Takekawa, S., & Kadowaki, T. (2005) · Endocrinology · doi:10.1210/en.2004-1096 · Cited by 319
Chen, J., Tan, B., Karteris, E., Zervou, S., Digby, J., Hillhouse, E. W., Vatish, M., & Randeva, H. S. (2006) · Diabetologia · doi:10.1007/s00125-006-0194-7 · Cited by 272 · cited 1×
“Although there is recent evidence for adiponectin production by cardiomyocytes [41] and placenta [42], the clinical significance of these findings remains to be elucidated.”
Background
Cited by
Manna, P., & Jain, S. K. (2015) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2015.0095 · Cited by 1,145
Boutari, C., & Mantzoros, C. S. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155217 · Cited by 1,068
“Epidemiologic studies have revealed an association between high body mass index (BMI) and an extensive range of chronic diseases such as Non Alcoholic Fatty Liver (NAFL), cardiovascular disease [1,2], diabetes mellitus [1], several malignancies [3,4], musculoskeletal diseases [5,6], chronic kidney disease [1], and men…”
Self-citationAdipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression
Vona-Davis, L., & Rose, D. P. (2007) · Endocrine-Related Cancer · doi:10.1677/erc-06-0068 · Cited by 496
“Mantzoros and colleagues (Barb et al. 2006, Kelesidis et al. 2006) showed that adiponectin can act on T47D breast cancer cells directly and alter downstream signaling pathways. The effects of adiponectin on growth were mediated by the activation of ERK1/2 and not by adenosine monophosphate-activated protein kinase (AM…”
BackgroundBlüher, M., & Mantzoros, C. S. (2015) · Metabolism · doi:10.1016/j.metabol.2014.10.016 · Cited by 399
Self-citationAdiponectin in relation to malignancies: a review of existing basic research and clinical evidence
Barb, D., Williams, C. J., Neuwirth, A. K., & Mantzoros, C. S. (2007) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/86.3.858s · Cited by 338
Self-citation
Metadata
- Authors
- Barb, D., Pazaitou-Panayiotou, K., & Mantzoros, C. S.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2006-07-21
- Volume
- 15
- Issue
- 8
- Pages
- 917-931
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2011382710
- Cited by
- 121
- References
- 30
- FWCI
- 5.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.